CMET-18. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Stevens, Glen, Pennell, Nathan, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Funchain, Pauline, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
CNS Metastasis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.219
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars